COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study

González‐Cao, María; Carrera, Cristina; Moreno, Juan Francisco Rodriguez; Rodríguez‐Jiménez, Pedro; Antoñanzas, Mónica; Feltes, Rosa; Puértolas, Teresa; Muñoz‐Couselo, Eva; Manzano, José Luís; Márquez-Rodas, Iván; Martín-Liberal, Juan; Soria, Ainara; Criado, Pilar Lopez; García‐Castaño, Almudena; Boada, Aram; Miguel, Pablo; Puig, Susana; Crespo, Guillermo; Fra, Pablo Luna; Zamora, Cristina Aguayo; Rodríguez, Marta Feito; Valles, Lara; Drozdowskyj, Ana; Maldonado-Seral, Cayetana; Gardeazábal, Jesús; Villalobos, L.; Rosell, Rafael; Fernández-Morales, L.A.; Rodrigo, Alberto; Viteri, Santiago; Provencio, Mariano; Berrocal, A.

doi:10.1016/j.jaad.2021.02.013

Cited by 5 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of 20,980 retrieved reports, 42 met study inclusion criteria 28 , 29 , 32 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 (Supplementary‐Figure 1). Study authors responded to requests to clarify the numbers and outcomes of IT patients receiving ICI therapy for 13 included reports 28 , 29 , 42 , 43 , 45 , 48 , 49 , 50 , 57 , 61 ,…”

Section: Resultsmentioning

confidence: 99%

“…There was moderate or greater heterogeneity ( I 2 ≥ 42%) among adjusted studies for survival and severe events. Overall, results were indirect since only 4 studies (10%) specifically examined the impact of ICI therapy on outcomes, 46 , 52 , 55 , 56 and 13 studies required clarification from authors regarding the number and outcomes of patients receiving ICIs among all IT patients. 28 , 29 , 42 , 43 , 45 , 48 , 49 , 50 , 57 , 61 , 62 , 66 , 67 Finally, these findings are imprecise since only 1 study included >100 ICI patients while 37 had <50 and 26 had <10 ICI patients.…”

Section: Resultsmentioning

confidence: 99%

“…81 Early data from several of these sources were included in the present analysis. 29 , 32 , 42 , 44 , 46 , 48 , 52 , 54 , 61 …”

Section: Discussionmentioning

confidence: 99%

“…81 Early data from several of these sources were included in the present analysis. 29,32,42,44,46,48,52,54,61 On the one hand, the persistence of SARS-CoV-2 variants and continued high infection rates coupled with the widespread use of ICIs for cancer emphasises the importance of understanding how prior ICI treatment alters COVID-19 outcomes in cancer patients. But these circumstances may provide a unique opportunity to understand whether ICIs should be considered for the treatment of other types of acute or chronic infections.…”

Section: Certainty Of Evidence (Grade) and Publication Biasmentioning

confidence: 99%

See 3 more Smart Citations

Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID‐19: Results of a systematic review and meta‐analysis

Minkove

Sun

et al. 2022

Reviews in Medical Virology

View full text Add to dashboard Cite

Background Determining how prior immune checkpoint inhibitor (ICI) therapy influences outcomes in cancer patients presenting with COVID‐19 is essential for patient management but must account for confounding variables. Methods We performed a systematic review and meta‐analysis of studies reporting adjusted effects of ICIs on survival, severe events, or hospitalisation in cancer patients with COVID‐19 based on variables including age, gender, diabetes mellitus, hypertension (HTN), chronic obstructive pulmonary disease, and other comorbidities. When adjusted effects were unavailable, unadjusted data were analysed. Results Of 42 observational studies (38 retrospective), 7 reported adjusted outcomes for ICIs and 2 provided sufficient individual patient data to calculate adjusted outcomes. In eight studies, adjusted outcomes were based on ≤7 variables. Over all studies, only one included >100 ICI patients while 26 included <10. ICIs did not alter the odds ratio (95%CI) (OR) of death significantly (random effects model), across adjusted ( n = 8) [1.31 (0.58–2.95) p = 0.46; I 2 = 42%, p = 0.10], unadjusted ( n = 30) [1.06 (0.85–1.32) p = 0.58; I 2 = 0%, p = 0.76] or combined [1.09 (0.88;1.36) p = 0.41; I 2 = 0%, p = 0.5)] studies. Similarly, ICIs did not alter severe events significantly across adjusted ( n = 5) [1.20 (0.30–4.74) p = 0.73; I 2 = 52%, p = 0.08], unadjusted ( n = 19) [(1.23 (0.87–1.75) p = 0.23; I 2 = 16%, p = 0.26] or combined [1.26 (0.90–1.77) p = 0.16; I 2 = 25%, p = 0.14] studies. Two studies provided adjusted hospitalisation data and when combined with 13 unadjusted studies, ICIs did not alter hospitalisation significantly [1.19 (0.85–1.68) p = 029; I 2 = 5%, p = 0.40]. Results of sensitivity analyses examining ICI effects based on 5 variables were inconclusive. Certainty of evidence was very low. Conclusions Across studies with adjusted and unadjusted results, ICIs did not alter outcomes significantly. But studies with comprehensive adjusted outcome data controlling for confounding variables are necessary to determine whether ICIs impact COVID‐19 outcomes in cancer patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…81 Early data from several of these sources were included in the present analysis. 29 , 32 , 42 , 44 , 46 , 48 , 52 , 54 , 61 …”

Section: Discussionmentioning

confidence: 99%

Section: Certainty Of Evidence (Grade) and Publication Biasmentioning

confidence: 99%

See 2 more Smart Citations

Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID‐19: Results of a systematic review and meta‐analysis

Minkove

Sun

et al. 2022

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…Figure 1 shows the PRISMA flow chart for the study screening and selection process in this research. Twenty-three trials including 19 retrospective studies [21] , [23] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] and 4 prospective studies [22] , [42] , [43] , [44] , enrolling 117735 study subjects ultimately met our criteria ( Figure 1 ). Six studies were performed in USA [25] , [26] , [29] , [31] , [35] , [40] , five in Italy [27] , [28] , [38] , [39] , [42] , four in Spain [27] , [36] , [37] , [43] , three in United Kingdom [22] , [33] , [34] , two in China [23] , [30] , one in France [41] , one in India [32] and one in Australia [21] .…”

Section: Resultsmentioning

confidence: 99%

Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis

Yang

Liu

Qin

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

Background Immune checkpoint inhibitors (ICIs) treatment among cancer patients has been shown to have antiviral effects by reactivating exhausted T cells. However, they could also trigger inflammatory storm. Therefore, prior exposure to ICIs may influence the risk of SARS-CoV2 infection and subsequent mortality. Recent results from studies of ICIs treatment on incidence and mortality of COVID-19 are controversial. Materials and methods We searched databases PubMed, Embase, ISI of Knowledge, Cochrane Central Register of Controlled Trials (CENTRAL), as well as pre-print databases (MedRxiv and BioRxiv) for retrospective and prospective studies comparing ICIs versus other antitumor treatments in cancer patients in the area of COVID-19 pandemic. The primary outcome was the incidence of COVID-19. The secondary outcomes were mortality of COVID-19. Results Twenty-three studies with a total of 117735 patients were selected. Compared with other antitumor treatments, prior exposure to ICIs had not an increased risk of incidence [Odds ratio (OR), 0.84; 95% confidence interval (CI), 0.60-1.18; P=0.32] and mortality (OR, 1.22; 95% CI, 0.91-1.62; P=0.18) of COVID-19 infectioin. Our subgroup and meta-regression analyses indicated that prior exposure to ICIs may reduce the incidence of COVID-19 in metastatic cancer patients. Conclusions There was no significant difference on incidence and mortality of COVID-19 between prior exposure to ICIs with other anti-tumor treatments. ICIs may reduce infection susceptibility of COVID-19 in metastatic cancer patients.

show abstract

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 (“GRAVID”). Methods The main objective was to describe the COVID-19 fatality rate in patients with melanoma throughout the pandemic, as well as to explore the effect of melanoma treatment and tumor stage on the risk of COVID-19 complications. These are the final data of the register, including cases from February 2020 to September 2021. Results One hundred-fifty cases were registered. Median age was 68 years (range 6–95), 61 (40%) patients were females, and 63 (42%) patients had stage IV. Thirty-nine (26%) were on treatment with immunotherapy, and 17 (11%) with BRAF-MEK inhibitors. COVID-19 was resolved in 119 cases, including 85 (57%) patients cured, 15 (10%) that died due to melanoma, and 20 (13%) that died due to COVID-19. Only age over 60 years, cardiovascular disorders, and diabetes mellitus increased the risk of death due to COVID-19, but not advanced melanoma stage nor melanoma systemic therapies. Three waves have been covered by the register: February–May 2020, August–November 2020, and December 2020–April 2021. The first wave had the highest number of registered cases and COVID-19 mortality. Conclusion Tumor stage or melanoma treatments are non-significant prognostic factors for COVID-19 mortality. During the pandemic in Spain there was a downward trend in the number of patients registered across the waves, as well as in the severity of the infection. Clinicaltrials.gov identifier NCT04344002. Supplementary Information The online version contains supplementary material available at 10.1007/s12094-022-02985-7.

show abstract

COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study

Cited by 5 publications

References 5 publications

Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID‐19: Results of a systematic review and meta‐analysis

Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID‐19: Results of a systematic review and meta‐analysis

Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

Contact Info

Product

Resources

About